Company reneges on promise to cut price of toxoplasmosis drugBMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h6472 (Published 30 November 2015) Cite this as: BMJ 2015;351:h6472
- Owen Dyer
Turing Pharmaceuticals, the company that drew condemnation from all sides in the United States two months ago when it bought the toxoplasmosis drug pyrimethamine (Daraprim) and raised the price by over 5000%,1 has abandoned a commitment to lower the drug’s list price by Christmas, instead opting to reduce the price charged to hospitals and offering expanded support to patients who lack health insurance or financial resources.
The changes were dismissed as “window dressing” by the HIV Medicine Association. “This medication can be made for pennies. They need to reduce the price to what it was before,” said the virologist Carlos Del Rio, the group’s chairman, in a statement. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial